- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03633773
Safety and Efficacy Evaluation of MUC-1 CART in the Treatment of Intrahepatic Cholangiocarcinoma
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
Zhejiang
-
Hangzhou, Zhejiang, China, 310009
- Recruiting
- The Second Affiliated Hospital of Zhejiang University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age 18-65 years old.
- The expression of ST glycosylated MUC-1 was more than 1+ in immunohistochemistry(IHC) by applicant-approved laboratory.
- Histopathology or cytology confirmed intrahepatic cholangiocarcinoma.
- Patients who are unable to perform surgery or are not suitable for surgery, or who have recurrence after surgery, or who are unwilling to undergo chemotherapy.
- With at least one extracranial measurable lesion according to RECIST 1.1 edition.
- The expected survival time is more than 60 days.
- The main organs are functional and meet the following criteria:
1) ECOG physical fitness score was 0~1 or KPS score >70. 2) Routine blood tests were in accordance with the following criteria: HB (>90 g/L) (no blood transfusion within 14 days), ANC (>1.5 x10^9/L), PLT (> 80 x10^9/L), lymphocyte (> 0.7 x10^9/L), LY (> 15%), Alb (> 2.8 g/dL), serum lipase and amylase < 1.5^ULN (upper limit of normal value).
3) Biochemical examination should meet the following criteria: TBIL < 1.5x ULN (upper limit of normal value); ALT < 2.5 xULN; serum Cr<1 xULN; endogenous creatinine clearance > 50ml/min (Cockcroft-Gault formula).
4) Cardiac ejection fraction >55%. 8. No active hemorrhagic disease or severe coagulation dysfunction. 9. No allergy to the contrast media. 10. Women of childbearing age must undergo a pregnancy test (serum or urine) within 7 days before enrollment, and the results are negative, and are willing to use appropriate contraception methods during the experiment and 8 weeks after the last CART.
11. The volunteers voluntarily joined the study, signed informed consent, and had good compliance and follow-up.
Exclusion Criteria:
- The transduction efficiency of T cells was <10% or T cells expanded less than 5 times after culture.
- Chimeric antigen receptor therapy or other transgenic T cell therapy.
- Pregnant or lactating women.
- In the first 4 weeks before the start of the study, they took part in other drug clinical trials.
- Patients with hypertension who can not be well controlled by a single antihypertensive drug (SBP> 140 mmHg, DBP> 90 mmHg), myocarditis or congenital heart disease, myocardial ischemia or infarction above grade I, arrhythmia above grade I (including QT interval < 440 ms) or cardiac insufficiency.
- Long term unhealed wounds or fractures.
- With a history of psychotropic substance abuse and unable to quit or have a history of mental disorders.
- Past and current objective evidence of pulmonary fibrosis, interstitial pneumonia, pneumoconiosis, radiation pneumonia, drug-related pneumonia, severe impairment of lung function, etc.
- With uncontrollable fungi, bacteria, viruses or other infections, or need antibacterial treatment. The presence of simple urinary tract infections and uncomplicated bacterial pharyngitis is allowed after consultation with a medical supervisor, if there is a response to active therapy.
- According to the NCI-CTCAE 4.0 standard, the patients who had used chemotherapy in the past had grade 2 hematological toxicity or grade 3 non-hematological toxicity.
- With a history of HIV or hepatitis B or hepatitis C virus infection.
- There are any indwelling catheters or drainage tubes (e.g. percutaneous nephrostomy, Frey's catheter, bile drainage or pleural/peritoneal/pericardial catheter). The use of dedicated central venous catheters is permitted.
- With brain metastases.
- With a history or disease of CNS, such as epileptic seizures, cerebral ischemia/hemorrhage, dementia, cerebellar disease, or any autoimmune disease involving CNS.
- With a major immunodeficiency.
- The main therapeutic drugs in this study (including fludarabine, cyclophosphamide, sodium mesylate, tropizumab and anti-infective drugs used during pretreatment) had a history of severe hypersensitivity.
- In the first 6 months of admission, there was a history of deep venous thrombosis or pulmonary embolism.
- History of autoimmune diseases (e.g. Crohn's disease, rheumatoid arthritis, systemic lupus erythematosus) that cause terminal organ injury or require systemic immunosuppressive/systemic disease-regulating drugs.
- With any diseases that may interfere with the safety or efficacy of treatment.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: MUC-1 CART
Patients are given fludarabine and cyclophosphamide as pretreatment before MUC-1 CART immunotherapy.
After treatment, specific antibodies, CART cells and serum levels of cytokines will be assessed.
|
After fludarabine and cyclophosphamide pre-chemotherapy,MUC-1 CART immunotherapy is given.
A decent interval later, levels of specific antibodies, CART cells and serum cytokines will be assessed.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Disease control rate
Time Frame: Up to approximately 12 months
|
Percentage of patients whose cancer doesn't progress after treatment
|
Up to approximately 12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Objective response rate
Time Frame: Up to approximately 12 months
|
Percentage of patients whose cancer shrinks or disappears after treatment
|
Up to approximately 12 months
|
Duration of overall response
Time Frame: Up to approximately 12 months
|
The time of initial response until documented tumor progression.
|
Up to approximately 12 months
|
Progression-free survival
Time Frame: Up to approximately 12 months
|
The percentage of people does not get worse for a period of time after diagnosis
|
Up to approximately 12 months
|
Overall survival
Time Frame: Up to approximately 12 months
|
The percentage of people still alive for a given period of time after diagnosis
|
Up to approximately 12 months
|
Common Toxicity Criteria for Adverse Effects
Time Frame: Up to approximately 12 months
|
According to Common Toxicity Criteria for Adverse Effects version 4
|
Up to approximately 12 months
|
EORTC QLQ - PAN26
Time Frame: Up to approximately 12 months
|
Assessed by the European Organization for Research and Treatment of Cancer Quality of Life
|
Up to approximately 12 months
|
Anti-MUC1 CART cell antibody
Time Frame: Up to approximately 12 months
|
Serum level of anti-MUC1 CART cell antibody
|
Up to approximately 12 months
|
MUC1 CART cell
Time Frame: Up to approximately 12 months
|
Serum level of MUC-1 CART cell
|
Up to approximately 12 months
|
Related cytokine
Time Frame: Up to approximately 12 months
|
Serum level of related cytokine(like IL-2、IL-6、TNF-α、IFNγ and so on)
|
Up to approximately 12 months
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- SAHZJU-Y2018-078
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Intrahepatic Cholangiocarcinoma
-
M.D. Anderson Cancer CenterActive, not recruitingStage III Intrahepatic Cholangiocarcinoma AJCC v8 | Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8 | Stage IIIB Intrahepatic Cholangiocarcinoma AJCC v8 | Stage IV Intrahepatic Cholangiocarcinoma AJCC v8 | Metastatic Intrahepatic Cholangiocarcinoma | Locally Advanced Intrahepatic CholangiocarcinomaUnited States
-
Mayo ClinicNational Cancer Institute (NCI)Not yet recruitingStage III Intrahepatic Cholangiocarcinoma AJCC v8 | Stage IV Intrahepatic Cholangiocarcinoma AJCC v8 | Unresectable Intrahepatic Cholangiocarcinoma | Locally Advanced Intrahepatic Cholangiocarcinoma | Oligometastatic Intrahepatic CholangiocarcinomaUnited States
-
Emory UniversityNational Cancer Institute (NCI)WithdrawnStage II Intrahepatic Cholangiocarcinoma AJCC v8 | Stage III Intrahepatic Cholangiocarcinoma AJCC v8 | Resectable Intrahepatic Cholangiocarcinoma | Stage 0 Intrahepatic Cholangiocarcinoma AJCC v8 | Stage I Intrahepatic Cholangiocarcinoma AJCC v8United States
-
Emory UniversityNational Cancer Institute (NCI); National Institutes of Health (NIH); CelgeneActive, not recruitingResectable Cholangiocarcinoma | Stage IB Intrahepatic Cholangiocarcinoma AJCC v8 | Stage II Intrahepatic Cholangiocarcinoma AJCC v8 | Stage III Intrahepatic Cholangiocarcinoma AJCC v8 | Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8 | Stage IIIB Intrahepatic Cholangiocarcinoma AJCC v8United States
-
Massachusetts General HospitalTerminatedResectable Intrahepatic Cholangiocarcinoma | Unresectable Intrahepatic CholangiocarcinomaUnited States
-
OHSU Knight Cancer InstituteOregon Health and Science UniversityActive, not recruitingStage III Intrahepatic Cholangiocarcinoma AJCC v8 | Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8 | Stage IIIB Intrahepatic Cholangiocarcinoma AJCC v8 | Liver and Intrahepatic Bile Duct Carcinoma | Stage IV Intrahepatic Cholangiocarcinoma AJCC v8 | Unresectable Intrahepatic CholangiocarcinomaUnited States
-
National Cancer Institute (NCI)CompletedStage III Intrahepatic Cholangiocarcinoma AJCC v8 | Gallbladder Carcinoma | Metastatic Cholangiocarcinoma | Stage IV Intrahepatic Cholangiocarcinoma AJCC v8 | Unresectable CholangiocarcinomaUnited States
-
NRG OncologyNational Cancer Institute (NCI)TerminatedStage III Intrahepatic Cholangiocarcinoma | Stage IVA Intrahepatic CholangiocarcinomaUnited States, Canada
-
City of Hope Medical CenterNational Cancer Institute (NCI)WithdrawnBile Duct Adenocarcinoma | Stage III Intrahepatic Cholangiocarcinoma | Stage IVA Intrahepatic Cholangiocarcinoma | Stage IVB Intrahepatic CholangiocarcinomaUnited States
-
Rutgers, The State University of New JerseyRecruitingIntrahepatic Cholangiocarcinoma | Cholangiocarcinoma, IntrahepaticUnited States
Clinical Trials on MUC-1 CART cell immunotherapy
-
Hadassah Medical OrganizationVaxil Therapeutics Ltd.WithdrawnMultiple Myeloma | TumorsIsrael
-
Fuda Cancer Hospital, GuangzhouWithdrawnGD2 Positive Glioma | CAR-T Cell ImmunotherapyChina
-
The Affiliated Hospital of Xuzhou Medical UniversityXuzhou Medical UniversityRecruiting
-
Fuda Cancer Hospital, GuangzhouWithdrawnCAR-T Cell Immunotherapy | GPC3 Positive Hepatocellular CarcinomaChina
-
Assistance Publique - Hôpitaux de ParisCompletedColorectal CancerFrance
-
The Republican Research and Practical Center for...Belarusian State Medical UniversityCompletedPancreatic Neoplasms | Dendritic CellsBelarus
-
The Affiliated Hospital of Xuzhou Medical UniversityXuzhou Medical UniversityRecruiting
-
The Affiliated Nanjing Drum Tower Hospital of Nanjing...Recruiting
-
Fuda Cancer Hospital, GuangzhouWithdrawnCAR-T Cell Immunotherapy | EphA2 Positive Malignant GliomaChina
-
First Affiliated Hospital of Chengdu Medical CollegeUnknownGastric Cancer | Pancreatic Cancer | Prostate Cancer | Colon Cancer | Esophageal Carcinoma | Hepatic CarcinomaChina